Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone415-818-1001
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees207
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions
What is Audentes Therapeutics' stock symbol?
Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."
How were Audentes Therapeutics' earnings last quarter?
Audentes Therapeutics Inc (NASDAQ:BOLD) released its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($1.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.23. During the same quarter last year, the company posted ($0.74) EPS. View Audentes Therapeutics' Earnings History.
When is Audentes Therapeutics' next earnings date?
What price target have analysts set for BOLD?
15 Wall Street analysts have issued twelve-month target prices for Audentes Therapeutics' shares. Their predictions range from $20.00 to $57.00. On average, they expect Audentes Therapeutics' stock price to reach $39.9931 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for Audentes Therapeutics.
What is the consensus analysts' recommendation for Audentes Therapeutics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Audentes Therapeutics.
What are Wall Street analysts saying about Audentes Therapeutics stock?
Here are some recent quotes from research analysts about Audentes Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our $44 (raised from $33) price target on shares of Audentes is based on a 12-year DCF-based, sum-of-the-parts analysis, which includes AT132 being developed for XLMTM and AT845, that is being advanced as a one-and-done approach for Pompe disease. Note, our prior $33 target, did not reflect AT-845. Our DCF is driven by a: beta of 1.25, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2028." (3/18/2019)
- 2. According to Zacks Investment Research, "Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company's product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. " (3/12/2019)
- 3. Mizuho analysts commented, "We spoke with management following yesterday’s regulatory update on AT132. Audentes held an encouraging first meeting with regulators and will continue to enroll patients in the high-dose cohort 2. Six-month biopsy data from this high- dose cohort is expected in 2Q19 and will help inform an optimal dose of AT132. Audentes then plans to submit an updated data package to the FDA, after which a second FDA meeting will be held; we anticipate this could happen in 3Q19 and we expect minutes from this meeting will provide more clarity around the pathway to a BLA filing for AT132. This could be an important catalyst in 2019. In the meantime, the next data update will be ASGCT." (2/1/2019)
Has Audentes Therapeutics been receiving favorable news coverage?
News articles about BOLD stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Audentes Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Audentes Therapeutics' key competitors?
Some companies that are related to Audentes Therapeutics include bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Orchard Therapeutics (ORTX) and Regenxbio (RGNX).
What other stocks do shareholders of Audentes Therapeutics own?
Who are Audentes Therapeutics' key executives?
Audentes Therapeutics' management team includes the folowing people:
- Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
- Ms. Natalie C. Holles, Pres & COO (Age 46)
- Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
- Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
- Mr. Andrew H. Chang, Director of Investor Relations
When did Audentes Therapeutics IPO?
(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Audentes Therapeutics' major shareholders?
Audentes Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.56%), BlackRock Inc. (6.63%), Redmile Group LLC (6.18%), FMR LLC (5.96%), Gilder Gagnon Howe & Co. LLC (3.66%) and Jennison Associates LLC (3.06%). Company insiders that own Audentes Therapeutics stock include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson, Orbimed Advisors Llc and Suyash Prasad. View Institutional Ownership Trends for Audentes Therapeutics.
Which major investors are selling Audentes Therapeutics stock?
BOLD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Versant Venture Management LLC, Citigroup Inc., BlackRock Inc., Wellington Management Group LLP, Schonfeld Strategic Advisors LLC and Osterweis Capital Management Inc.. Company insiders that have sold Audentes Therapeutics company stock in the last year include David Nagler, John T Gray, Louis G Lange, Mary Newman, Matthew R Patterson and Suyash Prasad. View Insider Buying and Selling for Audentes Therapeutics.
Which major investors are buying Audentes Therapeutics stock?
BOLD stock was bought by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Redmile Group LLC, Jennison Associates LLC, Federated Investors Inc. PA, Spark Investment Management LLC, Assenagon Asset Management S.A., Marshall Wace North America L.P. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Audentes Therapeutics.
How do I buy shares of Audentes Therapeutics?
Shares of BOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Audentes Therapeutics' stock price today?
One share of BOLD stock can currently be purchased for approximately $39.94.
How big of a company is Audentes Therapeutics?
Audentes Therapeutics has a market capitalization of $1.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.
What is Audentes Therapeutics' official website?
How can I contact Audentes Therapeutics?
Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]
MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe BOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
